Wenting Yu

Counsel

Disclaimer

Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.

Wenting Yu is a corporate transactional lawyer specializing in securities offerings, venture financings, mergers and acquisitions and other corporate transactions. She regularly assists startup, midsize, and large companies across a variety of industries, including biotechnology, life sciences, Internet, mobile, software, semiconductor, electronic design automation (EDA), gaming, media and marketing. Wenting also has significant cross-border transaction experience, particularly with Cayman entities doing business in the U.S. and China.

Wenting provides her clients with innovative legal approaches to complex transactions. She is communicative and works diligently to produce successful results for her clients so that she can position them for success.

Languages

  • Mandarin Chinese

Admissions

Bar Admissions

  • California
  • New York

Education

  • Washington University School of Law, J.D., Dean's List
  • Washington University School of Law, LL.M., with honors
  • Shanghai Normal University, LL.B., with honors

Professional Activities

Extern

  • Office of Compliance Inspections and Examinations, Securities and Exchange Commission

Co-author

  • "Joint Ventures in Emerging Markets: the Keys to Success" (Financier Worldwide, June 2012)

Leadership

  • Advisor, Project Entrepreneur 2020 NYC, presented by UBS in partnership with The Female Founder Collective

Speaking Engagements

  • Panelist, “Technology,” The Future of U.S. and China Conference, Asia Society Northern California (January 14, 2021)

Life Sciences

  • Brii Biosciences Limited in its US$318 million IPO and listing on the Hong Kong Stock Exchange
  • Pharmaron in its US$137.5 million acquisition of US-based Absorption Systems
  • a specialty pharmaceutical company in its NASDAQ initial public offering
  • a drug development company in its US$117 million Series D and Series E financings and HK$867 million initial public offering
  • a multinational biotechnology company in its US$260 million Series A and Series B financings
  • a multinational biotechnology company in its US$120 million convertible note and equity financings, spin-off of CDMO business and related equity financings
  • a multinational gene and cell therapy company in its US$148 million Series Seed and Series A financings
  • a Chinese public drug R&D service company in its various strategic acquisitions of U.S. and U.K. CRO companies
  • a Hong Kong public medical device company in its various strategic acquisitions of U.S. target companies
VIEW MORE

Press Releases